| Literature DB >> 35563327 |
Amit Kumar Halder1,2, Ana S Moura1, Maria Natália D S Cordeiro1.
Abstract
Conventional in silico modeling is often viewed as 'one-target' or 'single-task' computer-aided modeling since it mainly relies on forecasting an endpoint of interest from similar input data. Multitasking or multitarget in silico modeling, in contrast, embraces a set of computational techniques that efficiently integrate multiple types of input data for setting up unique in silico models able to predict the outcome(s) relating to various experimental and/or theoretical conditions. The latter, specifically, based upon the Box-Jenkins moving average approach, has been applied in the last decade to several research fields including drug and materials design, environmental sciences, and nanotechnology. The present review discusses the current status of multitasking computer-aided modeling efforts, meanwhile describing both the existing challenges and future opportunities of its underlying techniques. Some important applications are also discussed to exemplify the ability of multitasking modeling in deriving holistic and reliable in silico classification-based models as well as in designing new chemical entities, either through fragment-based design or virtual screening. Focus will also be given to some software recently developed to automate and accelerate such types of modeling. Overall, this review may serve as a guideline for researchers to grasp the scope of multitasking computer-aided modeling as a promising in silico tool.Entities:
Keywords: moving average approach; multitasking in silico modeling; software; virtual screening
Mesh:
Year: 2022 PMID: 35563327 PMCID: PMC9099502 DOI: 10.3390/ijms23094937
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Box–Jenkins operators used in the different studies [24,29,30,31,32,33,34,35].
|
|
|
|---|---|
| ∆( |
|
| ∆( |
|
| ∆( | |
| ∆( | |
| ∆( | |
| ∆( | SD( |
Feature selection and machine learning tools used for moving average based multitasking modeling [12,21,44].
| Feature Selection Tools—Linear Models (LDA) | Machine Learning Tools—Non-Linear Models |
|---|---|
| Fast stepwise (FS) selection | Decision trees (DT) |
| Sequential forward selection (SFS) | Random forests (RF) |
| Genetic algorithm (GA) selection | Gradient boosting (GB) |
| Post-selection similarity search modification (PS3M) | Support vector machines (SVM) |
| Bernoulli naïve Bayes (NB) | |
| Artificial neural networks (ANN) | |
| Deep neural networks (DNN) |
Figure 1Examples of new anti-breast cancer leads suggested in the mtk-QSAR modeling study by Speck-Planche et al. [55].
Selected multitasking classification modeling studies in antimicrobial and antiviral research.
| Year | Methodology a | No. of Chemicals ( | Endpoint Responses c | Bio-Targets d | Acc (%) e | Ref. |
|---|---|---|---|---|---|---|
| 2013 | RBF-ANN | 8560 (10,918) | Anti-Enterococci activities and toxicological profiles | 92.30 | [ | |
| 2013 | RBF-ANN | 6974 (11,576) | Anti-Streptococci activities and toxicological profiles | Streptococci strains; | 98.08 | [ |
| 2013 | FS-LDA | 20,863 (34,629) | Anti-Mycobacterial activity and ADMET properties | 94.80 | [ | |
| 2014 | FS-LDA | 23,705 (37,834) | Anti-Escherichia coli activities and ADMET properties | 95.85 | [ | |
| 2014 | FS-LDA | 26,945 (48,874) | Anti-cocci activities | Gram-positive cocci strains; proteins; cell lines; laboratory animals; humans | 92.89 | [ |
| 2014 | LNN-LDA | 21,582 (43,249) | Anti-HIV-1 activity and epidemiological profile | Viral or human proteins/enzymes (e.g., CC-CKR-5, HIV-1 RT, and HIV-1 PR); laboratory animals; humans | 76.76 | [ |
| 2015 | FS-LDA | 30,738 (54,682) | Anti- | 90.62 | [ | |
| 2015 | FS-LDA | 22,009 (30,181) | Anti-NOMA activity and ADMET profiles | Bacteria linked to NOMA infections (e.g., | 92.12 | [ |
| 2016 | FS-LDA | 2123 (3592) | Anti-microbial peptides (AMP) activity and cytotoxicity | Gram-negative bacterial strains; mammalian cell types | 97.40 | [ |
| 2016 | FS-LDA | 1581 (2488) | AMP activity | Gram-positive bacterial strains | 94.57 | [ |
| 2017 | FS-LDA | 20,562 (29,682) | Anti-HIV activity and ADMET properties | HIV; proteins/enzymes; cell lines; laboratory animals; humans | 96.26 | [ |
| 2017 | FS-LDA | 29,863 (40,158) | Anti-Hepatitis C activity and ADMET properties | Hepatitis C; proteins/enzymes; mammalian cells | 95.35 | [ |
| 2020 | MLP-ANN | 18,798 (21,369) | Anti-malarial activity, cytotoxicity, and pharmacokinetic properties | 90.49 | [ |
RBF: radial basis function; ANN: artificial neural networks; FS-LDA: forward stepwise–linear discriminant analysis; LNN: linear neural networks; MLP: multilayer perceptron. b No. of chemicals: Number of chemicals with unique structures; Ndp: Number of data points considered in the modeling taking into account the experimental conditions. ADMET: absorption, distribution, metabolism, elimination, and toxicity; AMP: antimicrobial peptides. d CC-CKR-5: C−C chemokine receptor type 5; HIV-1 RT: HIV-1 reverse transcriptase; HIV-1 PR: HIV-1 protease; NOMA: cancrum oris; Mtb: Mycobacterium tuberculosis. e Average accuracy obtained from the training and prediction sets.
Figure 2Promising BET bromodomain inhibitory leads proposed in the mtk-QSAR modeling study by Scotti and co-worker [38].
Figure 3The virtual screening strategy adopted for the design of pan-AKT inhibition (left) and pan-MNK inhibition (right) [25].
Some in silico tools and webservers employed for multitasking modeling.
| Method | Software/Webserver |
|---|---|
| Pharmacophore mapping | PharmMapper [ |
| Molecular docking | AutoDock [ |
| Similarity search | SIMSEARCH [ |
| Molecular dynamics simulations | Amber [ |
| Homology modeling | SwissModel [ |
| Drug-likeness | SwissADME [ |
| Synthetic accessibility | SwissADME [ |
| Graph-based signature | MycoCSM [ |
Figure 4Screenshot of the latest version of QSAR-Co (version 1.1.0) [44].
Figure 5Screenshots of the Modules 1–3 graphic interface from the toolkit QSAR-Co-X [12].
Figure 6Screenshot of the latest version of the Windows software FRAMA [10,85].